Effects of Epigallocatechin Gallate (EGCG) on Urinary Bladder Urothelial Carcinoma―Next-Generation Sequencing and Bioinformatics Approaches

1. Introduction

Transitional cell carcinoma (TCC), also called urothelial carcinoma, is the most common type of genitourinary cancer. Common risk factors include cigarette smoking and chemical exposure. Worldwide, the annual incidence rates are approximately 9.0 and 2.2 per 100,000 persons for men and women, respectively; the annual mortality rates are reported to be 3.2 and 0.9 per 100,000 persons for men and women, respectively [1]. However, the incidence and mortality rates of bladder cancer vary across countries. For instance, in Taiwan, higher incidence of bladder cancer was found in black-foot disease endemic areas [2]. The recommendations on the clinical management of bladder cancer is based on its muscle invasiveness, classified as non-muscle-invasive or muscle-invasive bladder cancer. Approximately 75% of patients with newly diagnosed bladder cancer present with non-muscle-invasive disease and undergo transurethral resection of the bladder followed by adjuvant therapy, such as intravesical chemotherapy or bacillus Calmette–Guérin (BCG) immunotherapy, to reduce the risk of disease recurrence or progression [1]. In patients with muscle-invasive disease or disease progression, treatment options include radical cystectomy and neoadjuvant chemotherapy, but as patients potentially progressed to metastatic status, the survival rate drops [3]. The efficacy of chemotherapy may be limited by drug toxicity, resistance, and adverse effects, and so novel therapeutic strategies that enhance treatment efficacy or increase sensitivity to drugs are of high clinical importance.

Epigallocatechin gallate (EGCG) is a major bioactive polyphenolic compound found in green tea leaves, and the effect of EGCG and their synthetic analogs have been reported as potential anti-cancer agents in various cancer types through modulating and regulating multiple signaling pathways [4]. Regarding the potential effects of EGCG on the urinary tract system, flavonoid antioxidants including EGCG were reported to ameliorate cyclophosphamide-induced cystitis [5]. In addition, Bazi et al. claimed the protective effect of EGCG against bladder degeneration in rats [6], and the antioxidant effect against H₂O₂-induced oxidative stress through superoxide was observed in normal and malignant bladder cells [7]. In bladder cancer, EGCG inhibits proliferation and migration, and induces apoptosis of bladder cancer cells [8,9], and it also exerts cytotoxic effect and prevents intravesical tumor growth with similar efficacy to mitomycin C [10]. Sterilization through radiation could keep EGCG in a stable form and of benefit in treating superficial bladder cancer [11]. A recent phase II trial of polyphenol consisted primarily of EGCG administered in patients prior to bladder cancer surgery resulted in definite tissue accumulation and biologic activity of polyphenol [12]. The evidence suggested EGCG as a potential therapeutic agent for prevention of tumor implantation in bladder cancer.

To investigate the role and novel therapeutic targets of EGCG on bladder urothelial carcinoma, we conducted this study to explore the effect of EGCG on altered gene expression and microRNA expression profiles of bladder cancer cells using next generation sequencing (NGS), and further investigate functionally enriched biological themes using different bioinformatics database analyses.

2. Materials and Methods

2.1. Cell Culture and RNA Extraction

The BFTC-905 cells, human urinary bladder transitional cell carcinoma (TCC) cell line, purchased from Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures GmbH, Braunschweig, Germany), were cultured in 6 cm culture plates with Dulbecco’s Modified Eagle Medium and incubated in 37 °C incubator containing 5% CO₂. After 24 h of incubation, cells were treated either with vehicle alone or 100 μM of EGCG for 24 h. The cells were then harvested and total RNA extracted using TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA, USA), following instruction from the manufacturer. The quantity of extracted RNA was analyzed using ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and the quality of RNA was analyzed using Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA).

2.2. Next-Generation Sequencing

For NGS, library preparation and deep sequencing were carried out at Welgene Biotechnology Company (Taipei, Taiwan) following the protocol of Illumina (San Diego, CA, USA). In brief, sequencing for transcriptome was determined using sequencing-by-synthesis technology, and the sequencing data was generated by Welgene’s pipeline based on Illumina’s base calling program bcl2fastq v2.2.0. Trimmomatic version 0.36 was used for adaptor clipping and sequence quality trimming [13]. The read alignment was accomplished using HISAT2 to map sequencing reads to genomes [14], followed by differential expression analysis using Cuffdiff (Cufflinks version 2.2.1) [15] with genome bias detection/correction and Welgene in-house programs. The genes with low expression levels (<0.3 fragment per kilobase of transcript per million mapped reads (FPKM)) in both EGCG-treated and control BFTC-905 cells were excluded. The p-values were calculated by Cuffdiff with non-grouped sample using “blind mode”, where all samples were determined as replicates of a single global “condition” to build one model for statistical test [15]. Genes with p-values < 0.05 and fold-change >2.0 were determined as significantly differentially expressed. For small RNA sequencing, samples were prepared using Illumina sample preparation kit, following the TruSeq Small RNA Sample Preparation Guide. Reverse transcription and PCR amplification was performed after 3′ and 5′ adaptor ligation to RNA. The amplified cDNA constructs were size-fractionated and purified using 6% polyacrylamide gel electrophoresis. The bands containing 18–40 nucleotide RNA fragments were extracted and sequenced on an Illumina instrument with 75 base pair single-end reads. Sequencing data was processed with the Illumina software and trimmed for qualified reads using Trimmomatic version 0.36 [13]. The qualified reads were analyzed using miRDeep2 to clip the 3′ adapter sequence and eliminate reads shorter than 18 nucleotides [16]. The reads were then aligned to the human genome from the University of California, Santa Cruz (UCSC). Only reads that mapped perfectly to the genome five or less times were used for miRNA detection. The miRNAs with low expression levels (<1 normalized read per million (RPM)) in both EGCG-treated and control BFTC-905 cells were excluded. Those miRNAs with fold-change >2.0 were determined as differentially expressed.

2.3. Bioinformatics Databases

To determine the enriched biological functions and interaction networks of the differentially expressed genes, several bioinformatics databases were used, including Ingenuity Pathway Analysis (IPA) [17], OmicsNet [18], and Database for Annotation, Visualization and Integrated Discovery (DAVID) [19]. In addition, to predict miRNA targets, miRmap target prediction database (version 1.1) [20] was used, and those candidate miRNA–mRNA interactions were validated in two other target prediction databases, TargetScan [21] and miRDB [22].

3. Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation as well as the experimental conclusions that can be drawn.

3.1. Identification of Differentially Expressed Genes in EGCG-Treated Bladder TCC Cells

The expression profile of EGCG-treated and control bladder TCC cells were obtained from NGS results, and the FPKM performance between the two samples were presented in density plot in Figure 1A. To identify differentially expressed genes in EGCG-treated bladder TCC cells, the dysregulated genes were displayed in volcano plot (Figure 1B), and significantly dysregulated genes were selected under the criteria of at least two-fold change in EGCG treated cells and significant differential expression with p < 0.05. A total of 58 up-regulated and 50 down-regulated genes in EGCG-treated bladder TCC cells were identified. The heatmap of these 108 dysregulated genes were shown in the right panel of Figure 2.

3.2. Exploring Potentially Altered miRNA–mRNA Interactions in EGCG-Treated Bladder TCC Cells

The miRNA expression profile of EGCG-treated and control bladder TCC cells were simultaneously performed using NGS. Dysregulated miRNAs were selected under the criteria of at least two-fold change in EGCG treated cells and normalized read counts of more than 1 RPM. There were 59 up-regulated and 44 down-regulated miRNAs identified in EGCG-treated bladder TCC cells, and the heatmap of these 103 dysregulated miRNAs were displayed in the left panel of Figure 2. The putative targets of these dysregulated miRNAs were obtained from miRmap database, selecting those with miRmap scores ≥97.0 indicating high repression strength. The putative targets were then matched to significantly differentially expressed genes identified in the previous section. The intersection Venn diagram was shown in the middle panel of Figure 2, where 22 candidate genes with potential miRNA interactions were identified. A list of the 22 candidate genes along with their expression levels were shown in

Table 1. Candidate genes with potential miRNA interactions of epigallocatechin gallate (EGCG)-treated bladder transitional cell carcinoma (TCC) cells.

Gene Symbol	Gene Name	EGCG FPKM	Control FPKM	Fold-Change (EGCG/Control)
GTF2H2C	GTF2H2 family member C	1.38	0.00	137677.00
PRRT2	proline rich transmembrane protein 2	21.44	0.17	126.48
RASA4	RAS p21 protein activator 4	1.81	0.17	10.92
TMEM92	transmembrane protein 92	1.85	0.53	3.52
RGPD5	RANBP2-like and GRIP domain containing 5	2.70	0.78	3.47
SEPT3	septin 3	0.70	0.20	3.42
MGAT5B	mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B	0.69	0.23	2.95
GOLGA8B	golgin A8 family member B	2.59	0.93	2.79
TSPAN2	tetraspanin 2	2.23	0.91	2.45
SBNO2	strawberry notch homolog 2	2.08	0.91	2.28
PPM1K	protein phosphatase, Mg2+/Mn2+ dependent 1K	1.31	2.66	−2.04
FCGRT	Fc fragment of IgG receptor and transporter	2.05	4.95	−2.41
CDON	cell adhesion associated, oncogene regulated	0.91	2.25	−2.47
NMNAT2	nicotinamide nucleotide adenylyltransferase 2	1.06	3.45	−3.27
DLG2	discs large MAGUK scaffold protein 2	0.65	2.18	−3.33
ARRB1	arrestin beta 1	0.34	1.37	−4.01
RBPMS	RNA binding protein with multiple splicing	0.28	1.24	−4.45
TXNDC2	thioredoxin domain containing 2	0.13	0.68	−5.06
TNS1	tensin 1	0.10	0.72	−6.96
GIPR	gastric inhibitory polypeptide receptor	0.51	4.77	−9.44
NDUFS1	NADH: ubiquinone oxidoreductase core subunit S1	0.07	1.81	−26.61
KMO	kynurenine 3-monooxygenase	0.02	0.61	−33.32

EGCG, epigallocatechin gallate.

.

3.3. The 22 Candidate Genes were Involved in NAD Biosynthesis, Inflammatory Response and Cancer

To understand the involvement of the 22 candidate genes with potential miRNA interactions in EGCG-treated bladder TCC cells, these genes were uploaded to IPA software for core analysis. The top five canonical pathways were mainly related to nicotinamide adenine dinucleotide (NAD) biosynthesis; additionally, most of these genes were related to diseases and disorders in inflammatory response and cancer (

Table 2. Top five canonical pathways and diseases and disorders of 22 candidate genes.

Canonical Pathway	p-Value	Overlap	Molecules
NAD biosynthesis II	7.73 × 10−5	14.3%	KMO, NMNAT2
NAD biosynthesis III	5.67 × 10−3	16.7%	NMNAT2
NAD biosynthesis from 2-amino-3-carboxymuconate semialdehyde	6.62 × 10−3	14.3%	KMO
Thioredoxin pathway	6.62 × 10−3	14.3%	TXNDC2
NAD salvage pathway III	6.62 × 10−3	14.3%	NMNAT2
Diseases and Disorders	p-Value Range	Number of Molecules
Inflammatory response	3.36 × 10−2 to 1.86 × 10−4	8	TSPAN2, TNS1, MGAT5B, SBNO2, GIPR, FCGRT, ARRB1, KMO
Cancer	4.54 × 10−2 to 2.86 × 10−4	21
Organismal injury and abnormalities	4.54 × 10−2 to 2.86 × 10−4	21
Reproductive system disease	1.49 × 10−2 to 6.33 × 10−4	15
Dermatological diseases and conditions	2.62 × 10−2 to 8.26 × 10−4	14

). The network analysis grouped these genes into three sub-networks, where 20 genes were related to nervous system function and inflammatory response, as listed in

Table 3. Networks associated with 22 candidate genes in EGCG-treated bladder TCC cells.

	Top Diseases and Functions	Score	Focus Molecules	Molecules in Network
1	Nervous System Development and Function, Tissue Morphology, Neurological Disease	24	10	APP, ↓ARRB1, Akt, ↓CDON, Cytochrome bc1, ECE2, ↓GIPR, HNRNPL, Jnk, MYC, NDUFB8, ↓NDUFS1, NDUFS4, NEDD4, NFATC2, ↓NMNAT2, NTRK1, Nedd4, ↓PPM1K, ↑RASA4, ↑RGPD5, ↑TMEM92, ↑TSPAN2, Trhr2, XPO1, miR-1229-3p, miR-27a-3p, miR-3691-5p, miR-376b-5p, miR-4435, miR-4752, miR-550b-3p, miR-6811-3p, miR-8056, quinolinic acid
2	Inflammatory Response, Antimicrobial Response, Cellular Development	24	10	CDH1, ↓DLG2, EP300, F2RL1, ↓FCGRT, GOLGA8A/↑GOLGA8B, ↑GTF2H2C, GTF2H2C_2, Holo RNA polymerase II, IFNG, IL6, ↓KMO, MDM2, NFATC2, ↑PRRT2, ↑SBNO2, ↑SEPT3, SRC, ↓TNS1, ↓TXNDC2, XPO1, miR-103b, miR-1243, miR-1281, miR-1307-3p, miR-20a-3p, miR-217-5p, miR-3060-5p, miR-3187-3p, miR-4638-5p, miR-4684-3p, miR-4707-3p, miR-4743-3p, miR-499b-5p, miR-924
3	Connective Tissue Development and Function, Embryonic Development, Organismal Development	4	2	CAMK2B, CREB5, DMRT3, FNDC11, HOXA1, KRTAP12-2, KRTAP19-5, ↑MGAT5B, OTX1, PITX1, ↓RBPMS, TRIP13, miR-1285-3p, miR-3473b, miR-4749-3p, miR-485-5p, miR-6132, miR-6850-3p, miR-744-5p

The genes marked in bold were the candidate genes identified in EGCG-treated bladder TCC cells.

. The activation z-score was −0.128 for inflammatory response, which indicated inhibited inflammatory response among these candidate genes.

To investigate the interaction network among these candidate genes, the OmicsNet was used for protein–protein interaction (PPI) network generation using both InnateDB and STRING databases. The major PPI subnetwork from InnateDB was displayed in Figure 3, in which module-based explorer using WalkTrap algorithm identified ARRB1, MGAT5B, RBPMS, and NDUFS1 as central hubs of major subnetworks. Similarly, ARRB1 and NDUFS1 were also identified as central hubs among the two major PPI subnetworks from the STRING database (Figure 4). In addition, metabolite-protein interaction data was also investigated on all KEGG reactions in the OmicsNet. Among the interaction network, NDUFS1, KMO, and NMNAT2 were found closely associated with NAD related metabolites, as shown in Figure 5.

3.4. Enriched Biological Functions Among Differentially Expressed Genes in EGCG-Treated Bladder TCC Cells

To investigate functionally enriched biological themes among the 108 differentially expressed genes in EGCG-treated bladder TCC cells, IPA and DAVID databases were used. The IPA result identified NAD biosynthesis (p = 1.77 × 10⁻³) and Hippo signaling (p = 6.74 × 10⁻³) being the top canonical pathways, and cancer the top disease involved in these dysregulated genes (

Table 4. Top five canonical pathways and diseases and disorders of differentially expressed genes.

Canonical Pathway	p-Value	Overlap	Molecules
NAD biosynthesis II	1.77 × 10−3	14.3%	KMO, NMNAT2
Hippo signaling	6.74 × 10−3	3.5%	DLG2, SCRIB, SMAD1
Dopamine degradation	8.08 × 10−3	6.7%	ALDH1A1, SULT1A3
Spliceosomal cycle	9.01 × 10−3	50.0%	U2AF1
Asparagine degradation I	9.01 × 10−3	50.0%	ASPG
Diseases and Disorders	p-Value Range	Number of Molecules
Cancer	4.86 × 10−2 to 1.12 × 10−4	94
Organismal injury and abnormalities	4.86 × 10−2 to 1.12 × 10−4	96
Infectious diseases	4.42 × 10−2 to 1.08 × 10−3	3
Cardiovascular disease	4.42 × 10−2 to 1.62 × 10−3	13
Hereditary disorder	4.42 × 10−2 to 1.62 × 10−3	25

The genes marked in bold were the candidate genes identified in EGCG-treated bladder TCC cells.

). In the DAVID database analysis, the significantly enriched biological processes were also observed to be associated with oxidation-reduction process and NFκB signaling, and borderline significance in NAD metabolic process and metabolic pathways (

Table 5. Enrichment analysis of differentially expressed genes in Database for Annotation, Visualization and Integrated Discovery (DAVID) database.

Biological Process	Genes	p Value	Fold Enrichment
Oxidation-reduction process	P3H2, ALDH1A1, PXDN, TXNDC2, PYROXD2, NCF1, KMO, SDR9C7, PRODH	0.0108	2.934
Positive regulation of IκB kinase/NFκB signaling	CD36, EEF1D, GPR89A, S100A12	0.0497	4.795
NAD metabolic process	NMNAT2, KMO	0.0549	35.093
xenobiotic metabolic process	NAT1, SULT1A3, S100A12	0.0606	7424
carboxylic acid metabolic process	GAD1, PDXDC1	0.0646	29.694
response to fatty acid	CD36, GIPR	0.0836	22.707
superoxide metabolic process	IMMP2L, NCF1	0.0976	19.301
KEGG pathway	Genes	p value	Fold Enrichment
Metabolic pathways	ALDH1A1, NMNAT2, MGAT5B, NAT1, KMO, PLCD1, ITPK1, GAD1, POLR2J2, NDUFS1, PRODH	0.0651	1.774

The genes marked in bold were the candidate genes identified in EGCG-treated bladder TCC cells.

).

3.5. Identification of Potential miRNA Interactions in EGCG-Treated Bladder TCC Cells

To identify miRNAs potentially regulating the differentially expressed genes in EGCG-treated bladder TCC cells, several miRNA target prediction databases were used to determine miRNAs potentially regulating major hubs of the previously identified interaction networks, including ARRB1, RBPMS, MGAT5B, NDUFS1, TNS1, DLG2, NMNAT2, KMO, and PPM1K. Matching to the differentially expressed miRNAs in EGCG-treated bladder TCC cells, several of the miRNA regulations were consistently validated in miRmap, TargetScan and miRDB databases. The potential miRNA interactions were listed in

Table 6. Validation of potentially altered miRNA–mRNA interactions in EGCG-treated bladder TCC cells.

Putative mRNA	mRNA Fold Change (EGCG/Ctrl)	Predicted miRNA	miRNA Fold Change (EGCG/Ctrl)	miRmap Score	TargetScan	miRDB	Seed Region of 3′UTR
ARRB1	−4.01	hsa-miR-185-3p	3.92	98.87	Yes	Yes	815–821, 1723–1729
ARRB1	−4.01	hsa-miR-3139	2.88	98.04	Yes	No
RBPMS	−4.45	hsa-miR-3176	2.17	97.23	Yes	No
MGAT5B	2.95	hsa-miR-3116	−4.65	98.69	Yes	Yes	201–207, 492–499, 537–543, 1263–1270
MGAT5B	2.95	hsa-miR-6724-5p	−3.96	99.88	Yes	No
NDUFS1	−26.61	hsa-miR-1285-3p	3.43	97.99	Yes	No
TNS1	−6.96	hsa-miR-1285-3p	3.43	98.55	Yes	No
TNS1	−6.96	hsa-miR-18a-3p	3.13	99.36	Yes	No
TNS1	−6.96	hsa-miR-31-5p	2.14	97.84	Yes	Yes	2786–2793, 4195–4202
TNS1	−6.96	hsa-miR-3176	2.17	99.13	Yes	No
TNS1	−6.96	hsa-miR-642a-5p	8.27	99.85	Yes	Yes	137–144, 3071–3077, 3157–3164, 3437–3443, 4219–4225
DLG2	−3.33	hsa-miR-1226-3p	2.28	99.63	Yes	Yes	3812–3819, 3825–3831, 3846–3853
DLG2	−3.33	hsa-miR-484	2.68	80.73	Yes	Yes	1104–1110
NMNAT2	−3.27	hsa-miR-185-3p	3.92	98.12	Yes	No
NMNAT2	−3.27	hsa-miR-93-3p	2.64	97.35	Yes	No
KMO	−33.32	hsa-miR-18a-3p	3.13	97.34	Yes	No
PPM1K	−2.04	hsa-miR-22-3p	2.04	97.03	Yes	Yes	299–306

The genes marked in bold were the miRNA–mRNA interactions validated in all three miRNA prediction databases.

.

4. Discussion

The current study investigated the potential effects of EGCG on bladder urothelial carcinoma using NGS and bioinformatics analysis. A total of 108 differentially expressed genes in EGCG-treated bladder TCC cells were identified, and were mainly involved in NAD biogenesis, inflammatory response, and oxidation-reduction metabolism. In addition, miRNA target prediction analysis identified several miRNA–mRNA interactions that potentially participated in the response of bladder TCC to EGCG treatment, including miR-185-3p-ARRB1, miR-3116-MGAT5B, miR-31-5p-TNS1, miR-642a-5p-TNS1, miR-1226-3p-DLG2, miR-484-DLG2, and miR-22-3p-PPM1K. Of these genes with potential miRNA interactions, DLG2 was involved in Hippo pathway and inflammatory response, and TNS1, ARRB1, and MGAT5B were involved in inflammatory response. A schematic summary of the current study is illustrated in Figure 6.

NAD is an essential coenzyme participating in various energy metabolic pathways, cell signaling regulatory pathways and DNA repair, and a potential therapeutic target for oncotherapy [23]. Higher levels of NAD in cancer cells has been reported [24]. The high glycolytic rate of cancer cells, called “Warburg effect” requires NAD for glycolytic enzymes, and the NAD salvage pathway is important in cancer biology and an intriguing target to prevent cancer growth [23]. Nicotinamide nucleotide adenylyltransferase 2 (NMNAT2) is a cytosolic enzyme that assists in maintaining mitochondrial NAD level, although the association between NAD salvage pathway and mitochondrial NAD level remains unclear [23]. In osteosarcoma cells, knockdown of NMNAT2 reduced p53-mediated cell death upon DNA damage [25]. Interestingly, previous study has reported overexpression of NMNAT2 enhanced sensitivity of colorectal cancer cells to specific pro-drug and improved therapeutic efficacy [26]. In addition, reduced NAD level also activates signaling pathways promoting epithelial to mesenchymal transition (EMT), facilitating tumor progression [27]. In bladder cancer, the role of nicotinamide metabolism has recently been reported. The concentration of NAD in whole blood was decreased in patients with bladder cancer compared to control subjects, and plasma levels of nicotinamide metabolites were also altered [28]. NQO1, one of the major quinone reductases highly inducible under cellular stress, modulate NAD/NADH redox balance, and specific polymorphism of NQO1 is associated with cancer risk in urinary system [29]. However, the role of NMNAT2 in bladder cancer cells and whether expression of NMNAT2 affects therapeutic efficacy remains unclear.

Another important issue is reactive oxygen species (ROS) which is toxic to all cells, including cancer cells. Therefore, a good anti-oxidant defense system in cells is essential to prevent cytotoxic damage [23]. NAD is also involved in the regulation of oxidative stress, and report showed ascorbate induced cell death of neuroblastoma cells through NAD depletion and ROS-induced DNA damage, which suggested that NAD and ROS production are partially responsible for the cancer cell cytotoxicity [30]. The current evidence suggested the importance of NAD biosynthesis in cancer pathogenesis and NAD as potential biomarkers. Our analytic results also indicated the involvement of NAD biosynthesis and related oxidation-reduction process in EGCG-treated bladder TCC cells, which suggested the potential effect of EGCG in urothelial carcinoma through alteration in NAD and oxidation-reduction related metabolism.

Chronic inflammation plays an important role in cancer. The link between inflammation and development of bladder cancer has also been reported, and the oncogenic changes may potentiate inflammatory microenvironment that leads to angiogenesis and invasion of bladder cancer [31,32]. EGCG is a major constituent of green tea polyphenols that is documented as having antioxidant, anti-inflammatory, and anti-cancer effects [33]. The anti-inflammatory property is mainly through targeting toll-like receptor 4 signaling pathway, which is also associated with cancer progression [34]. In our current study, results suggested the involvement of inflammatory response among dysregulated genes with potential miRNA interactions, particularly TNS1, MGAT5B, and ARRB1, and the activation z-score was −0.128, indicating inhibited inflammatory response upon EGCG treatment.

Arrestin beta 1 (ARRB1) is one of the beta arrestins regulating various cellular physiologic processes, and have been demonstrated to have pro-tumorigenic effects [35,36]. Kallifatidis et al. recently reported increased ARRB1 expression in bladder cancer cells, and ARRB1 gene knockout reversed the aggressive phenotype of bladder cancer cell lines [37]. MiR-185-3p is a potential oncosuppressor miRNA evident in nasopharyngeal carcinoma (NPC), and the inhibition of miR-185-3p promoted invasion and metastasis of NPC cells [38]. In the current study, altered miR-185-3p-ARRB1 interaction was identified in EGCG-treated bladder TCC cells, with 3.92-fold up-regulated miR-185-3p and 4.01-fold suppressed ARRB1. The evidence suggested the potential effect of EGCG in altered miR-185-3p expression that may affect bladder TCC cells.

Down-regulation of tensin 1 (TNS1) potentially regulated by miR-31-5p and miR-642a-5p was also identified in the current study. The expression of TNS1 was found higher in colorectal cancer cell lines and tissues, and suppression of TNS1 decreased proliferation and invasiveness of cancer cells, while the level of TNS1 was positively associated with poor survival in patients with colorectal cancer, indicating TNS1 could potentially be a therapeutic target [39]. MiR-31-5p serves as an oncosuppressor miRNA and increases the sensitivity of bladder cancer cells to mitomycin C [40,41]. EGCG also exerted cytotoxic effect to bladder cancer cells with similar efficacy to mitomycin C [10]. This suggests that EGCG can be a potent adjunctive compound to mitomycin C in bladder cancer treatment through regulating miR-31-5p and its potential target TNS1. However, the role of miR-642a-5p in bladder cancer remains unclear, and further investigation is needed to clarify the role of miR-642a-5p-TNS1 interaction in bladder cancer in response to EGCG treatment.

In our current study, DLG2 (discs large homolog 2) potentially regulated by miR-1226-3p and miR-484, along with SCRIB and SMAD1, were associated with Hippo signaling (p = 6.74 × 10⁻³). The effect of EGCG in cancer treatment was validated from in vitro and in vivo studies [4]. The Hippo signaling pathway is found dysregulated in bladder cancer, causing cancer progression and chemotherapy resistance [42]. EGCG was proposed to affect cell proliferation and apoptosis through Hippo signaling pathway in oral cancer [43], but has not been studied in bladder cancer. While the role of DLG2 as a tumor suppressor gene in osteosarcoma [44] and miRNA target in ovarian cancer inhibiting cell migration [45] were reported, its involvement in bladder cancer remains unclear.

There are some limitations in the current study. Firstly, the current results were based on results from bladder cancer cell line, BFTC-905. Since genomic variability is an important issue in urothelial carcinoma, future study will be conducted on other bladder cancer cell lines and primary cells from patients with urothelial carcinoma for further investigation. In addition, experimental validation of potential targets and miRNAs in EGCG-treated bladder cancer cells is needed. Moreover, it is important to investigate the changes in gene expression in clinical specimens of patients with different bladder cancer stages to determine the therapeutic effect of EGCG.

5. Conclusions

In summary, 108 differentially expressed genes and 22 candidate genes with potential miRNA interactions in EGCG-treated bladder TCC cells were identified. These genes were mainly involved in NAD biogenesis, inflammatory response, and oxidation-reduction metabolism. Moreover, several miRNA–mRNA interactions that were potentially altered with EGCG treatment were identified. These findings may provide insights into novel therapeutic targets and underlying mechanisms of action of EGCG treatment in bladder cancer.